The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 10, 2019
Filed:
Mar. 30, 2018
Genentech, Inc., South San Francisco, CA (US);
Bryan Chan, Foster City, CA (US);
Naomi Rajapaksa, San Mateo, CA (US);
Michael Siu, San Francisco, CA (US);
Craig Stivala, San Mateo, CA (US);
John Tellis, San Mateo, CA (US);
Weiru Wang, Lafayette, CA (US);
BinQing Wei, Belmont, CA (US);
Aihe Zhou, San Jose, CA (US);
Matthew W. Cartwright, Harlow, GB;
Emanuela Gancia, Harlow, GB;
Graham Jones, Harlow, GB;
Blake Daniels, South San Francisco, CA (US);
Michael Lainchbury, Harlow, GB;
Andrew Madin, Harlow, GB;
Eileen Seward, Harlow, GB;
David Favor, Shanghai, CN;
Kin Chiu Fong, Shanghai, CN;
Andrew Good, Shanghai, CN;
Yonghan Hu, Shanghai, CN;
Baihua Hu, Beijing, CN;
Aijun Lu, Beijing, CN;
Joy Drobnick, Daly City, CA (US);
Lewis Gazzard, Belmont, CA (US);
Timothy Heffron, Burlingame, CA (US);
Malcolm Huestis, San Francisco, CA (US);
Jun Liang, Los Altos Hills, CA (US);
Sushant Malhotra, Burlingame, CA (US);
Rohan Mendonca, Pleasanton, CA (US);
Genentech, Inc., South San Francisco, CA (US);
Abstract
Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.